Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

APcK 110, a novel Inhibitor of Kit, Extends Survival of NOD-SCID Mice in An AML Xenograft Model.

Stefan Faderl, MD, Carlos Bueso-Ramos, MD, PhD, Zhiming Liu, Ashutosh Pal, William Bornmann, PhD, David Harris, Inbal Hazan-Halevy, PhD, Hagop M. Kantarjian, MD, Zeev Estrov, MD

Blood (2009) 114 (22): 1045.

https://doi.org/10.1182/blood.V114.22.1045.1045

Published: 2009

Journal Articles

A Novel Small-Molecule Approach To Inhibit Jak2 Tyrosine Kinase Signaling.

Vaibhav Kapuria, MS, Geoffrey Bartholomeusz, PhD, Ling-Yuan Kong, PhD, William Bornmann, PhD, Zhenghong Peng, PhD, Ashutosh Pal, PhD, David Maxwell, PhD, Moshe Talpaz, MD, Nicholas Donato, PhD

Blood (2007) 110 (11): 1556.

https://doi.org/10.1182/blood.V110.11.1556.1556

Published: 2007

Journal Articles

Degrasyn-Induced Trafficking of BCR-ABL as a Novel Mechanism of Kinase Inactivation.

Nicholas Donato, PhD, Vaibhav Kapuria, MS, Hanshi Sun, PhD, David Maxwell, PhD, Geoffrey Bartholomeusz, PhD, William Bornmann, PhD, Zhenghong Peng, PhD, Ashutosh Pal, PhD, Moshe Talpaz, MD

Blood (2007) 110 (11): 1003.

https://doi.org/10.1182/blood.V110.11.1003.1003

Published: 2007

Journal Articles

Structure-Based Drug Design of c-Kit Inhibitors for Use in the Treatment of Acute Myeloid Leukemia.

David S. Maxwell, PhD, Ashutosh Pal, Zhenghong Peng, Alexandr Shavrin, Stefan Faderl, MD, David Harris, Quin Van, Zhiming Liu, Srdan Verstovsek, MD PhD, Taghi Manshouri, MB BS, Alessandra Ferrajoli, MD, Hagop M. Kantarjian, MD, Zeev Estrov, MD, William G. Bornmann, PhD

Blood (2006) 108 (11): 1906.

https://doi.org/10.1182/blood.V108.11.1906.1906

Published: 2006

Journal Articles

APCK110, a Novel and Potent Inhibitor of c-Kit, Blocks Phosphorylation of AKT and STAT3, Induces Apoptosis, and Inhibits Proliferation of Acute Myeloid Leukemia (AML) Cells.

Stefan Faderl, MD, William Bornmann, PhD, David Maxwell, PhD, Ashutosh Pal, Zheng-Hong Peng, Aleksandr Shavrin, David Harris, Quin Van, Liu Zhiming, Srdan Verstovsek, MD, PhD, Taghi Manshouri, MS, BS, Alessandra Ferrajoli, MD, Hagop M. Kantarjian, MD, Zeev Estrov, MD

Blood (2006) 108 (11): 153.

https://doi.org/10.1182/blood.V108.11.153.153

Published: 2006

NARROW

APcK 110, a novel Inhibitor of Kit, Extends Survival of NOD-SCID Mice in An AML Xenograft Model.

A Novel Small-Molecule Approach To Inhibit Jak2 Tyrosine Kinase Signaling.

Degrasyn-Induced Trafficking of BCR-ABL as a Novel Mechanism of Kinase Inactivation.

Structure-Based Drug Design of c-Kit Inhibitors for Use in the Treatment of Acute Myeloid Leukemia.

APCK110, a Novel and Potent Inhibitor of c-Kit, Blocks Phosphorylation of AKT and STAT3, Induces Apoptosis, and Inhibits Proliferation of Acute Myeloid Leukemia (AML) Cells.

Email alerts

ASH Publications

American Society of Hematology

APcK 110, a novel Inhibitor of Kit, Extends Survival of NOD-SCID Mice in An AML Xenograft Model.

A Novel Small-Molecule Approach To Inhibit Jak2 Tyrosine Kinase Signaling.

Degrasyn-Induced Trafficking of BCR-ABL as a Novel Mechanism of Kinase Inactivation.

Structure-Based Drug Design of c-Kit Inhibitors for Use in the Treatment of Acute Myeloid Leukemia.

APCK110, a Novel and Potent Inhibitor of c-Kit, Blocks Phosphorylation of AKT and STAT3, Induces Apoptosis, and Inhibits Proliferation of Acute Myeloid Leukemia (AML) Cells.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only